In 2023, results from the RATIONALE-312 study showed that the programmed cell death-1 (PD-1) inhibitor tislelizumab in combination with chemotherapy prolonged the median OS of patients to 15.5 months, thus achieving a significant improvement in survival in patients with ES-SCLC (8). This evidence concerns the gene PDCD1 and small cell lung carcinoma.